Toronto · Independent Shariah screening · Screened October 1, 2026

TSX Shariah screener · October 2026

Apotex Health Corp.

APTX · TSX · Healthcare

FAIL

Is Apotex Health Corp. (APTX) Halal?

Debt ÷ market cap 34% / 33%

Apotex Health Corp. · TSX: APTX · Healthcare

Price chart by TradingView · Market data may be delayed · Shown for information only — not investment advice.

The short answer

No — Apotex Health (APTX) fails this Shariah stock screen on the debt gate. Its generics, biosimilars, branded pharma, and consumer health business is permissible, but total debt of C$2,433.4M at Q1 FY2027 is about 34% of its ~C$7.16B market cap — over the ~33% ceiling. This is a knife-edge fail (33.5–34% across price/share-count variants), so it is a re-screen candidate if the share price rises or debt falls. No Zoya, Musaffa, or ShariaPortfolio rating was found for this ticker — honestly reported as absent, not invented.

Gate 1 — Business activity: PASS

Apotex Health Corp. (TSX:APTX) is a pharmaceutical company — generics, biosimilars, branded pharma, and consumer health products. It began trading June 10, 2026 after an upsized IPO of 62,291,670 shares at C$24.00 (C$1.495B — the largest Canadian IPO since 2021). No alcohol, pork, gambling, conventional interest-based lending, tobacco, cannabis, weapons, or adult-entertainment lines were disclosed. Gate 1 passes. Facts only.

Gate 2 — Debt and cash: FAIL

Total debt at Q1 FY2027 (three months ended June 30, 2026) was C$2,433.4M. Against a market capitalization of roughly C$7.16B (~230M non-diluted shares post-IPO at C$31.13, October 1, 2026), debt ÷ market cap is about 34% — over the ~33% ceiling. The result is knife-edge (33.5–34% across price and share-count variants), but consistently above the ceiling. Cash of C$258.8M is about 3.6% of market cap. Gate 2 fails. Facts only.

Gate 3 — Non-compliant income: Not assessed — debt gate decisive

With the debt gate failed, the income ratio does not change the outcome. For reference, the Q1 FY2027 release reports only 'interest expense, net C$62.0M' — no separately disclosed interest-income line was located. No income ratio is asserted here. Facts only.

BDS screen

Whether this company appears on boycott, divestment and sanctions (BDS) lists. Informational only — it does not change the Shariah screening result above, and it is not a religious ruling.

No BDS listing found on the BDS movement's published boycott, divestment, or pressure lists (checked October 2026).

Moral screen

Beyond the Shariah financial gates, this checks the company’s documented business ties to the Israeli and US militaries, and to weapons manufacturing. Every finding is factual and sourced. A row with no finding means none surfaced in our review — not proof of none.

Israeli military business
No findings published.
US military business
No findings published.
Weapons manufacturing & arms trade
No findings published.

Key figures used

Halal alternatives in this sector

APTX did not pass the screen. These companies in the same sector passed:

Frequently asked questions

Is Apotex Health (APTX) halal?

No. Apotex Health fails this Shariah stock screen on the debt gate. Its generics, biosimilars, branded pharma, and consumer health business is permissible, but total debt of C$2,433.4M at Q1 FY2027 is about 34% of its ~C$7.16B market cap — over the ~33% ceiling. This is a knife-edge fail (33.5–34% across price/share-count variants), so it is a re-screen candidate if the share price rises or debt falls. This is a factual screen, not a religious ruling — consult a qualified scholar for personal guidance.

What is Apotex Health's debt-to-market-cap ratio?

About 34%. Total debt at Q1 FY2027 (three months ended June 30, 2026) was C$2,433.4M, against a market cap of roughly C$7.16B (~230M non-diluted shares post-IPO at C$31.13, October 1, 2026) — over the ~33% ceiling. Knife-edge: 33.5–34% across price and share-count variants.

What does Apotex Health do?

Apotex Health Corp. (TSX:APTX) is a pharmaceutical company — generics, biosimilars, branded pharma, and consumer health products. It began trading June 10, 2026 after an upsized IPO of 62,291,670 shares at C$24.00 (C$1.495B — the largest Canadian IPO since 2021).

How much interest income does Apotex Health earn relative to revenue?

No income ratio is asserted in this screen: the Q1 FY2027 release reports only 'interest expense, net C$62.0M' with no separately disclosed interest-income line, and the debt-gate failure is decisive.

Where can I find more healthcare stock screeners?

See halal-stock-verdicts.html for the full list of stock screeners, including the other healthcare-sector entries.

Sources

Screened 2026-10-01 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.